Phosphodiesterase inhibitors

Lennham Pharmaceuticals Announces Topline Results from Pharmacokinetic Study of d9-Caffeine Versus Caffeine

Retrieved on: 
Monday, June 7, 2021
FDA, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Psychoactive drugs, Drugs, Stimulants, Phosphodiesterase inhibitors, Xanthines, Caffeine, Mutagens

Lennham Pharmaceuticals today announced topline results of the first ever human study of d9-caffeine.

Key Points: 
  • Lennham Pharmaceuticals today announced topline results of the first ever human study of d9-caffeine.
  • The study was conducted to compare the single-dose pharmacokinetics of caffeine versus d9-caffeine and their corresponding metabolites in healthy adult volunteers.
  • Unlabeled caffeine or d9-caffeine at two dose levels were administered with blood samples collected before and up to 48 hours after administration.
  • The effects of caffeine on drowsiness in patients with narcolepsy: a double-blind randomized controlled pilot study.

Altitude Dials Back the Need for Caffeine

Retrieved on: 
Thursday, March 25, 2021
Psychoactive drugs, Drugs, Caffeine, Phosphodiesterase inhibitors, Stimulants, Xanthines, Mutagens, Energy drink

There are many ways that caffeine has weaseled its way into the modern mindset.

Key Points: 
  • There are many ways that caffeine has weaseled its way into the modern mindset.
  • It's a fact that the founders of Altitude had in mind when they created their groundbreaking energy solution Altitude.
  • On the contrary, the body only needs roughly 25 to 35 mg of caffeine at any given moment to stay awake.
  • Over the years since its inception, Altitude has proven itself to be a powerful breakthrough in the energy drink industry.

Grey Cloak Tech Releases Study of Fuel4Thought Brain Booster

Retrieved on: 
Tuesday, December 8, 2020
Branches of biology, Psychoactive drugs, Drugs, Phosphodiesterase inhibitors, Stimulants, Xanthines, Caffeine, Mutagens, Brain

Fuel4Thought Brain Booster Provides Astounding Brain Activation Improvement of 49% with Its Revolutionary 2.5 oz Formulation with Zero Caffeine, Zero Sugar and Zero Crash

Key Points: 
  • Fuel4Thought Brain Booster Provides Astounding Brain Activation Improvement of 49% with Its Revolutionary 2.5 oz Formulation with Zero Caffeine, Zero Sugar and Zero Crash
    LAS VEGAS, NV, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire Grey Cloak Tech Inc. (OTCQB: GRCK ) (soon to be Healthy Extracts Inc .
  • Dr. James Rouse, Medical Advisory Board President and renowned Iron Man Triathlete, said: Fuel4Thought is the varsity of brain nutrition.
  • F4T Brain Booster provides the best nourishment possible without the negative ingredients of sugar and caffeine.
  • It reduces inflammation in the brain, energizes the brain, sharpens focus, enhances memory, improves concentration, and increases productivity.

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Evolving Opportunities with AstraZeneca and Merck | Technavio

Retrieved on: 
Friday, January 17, 2020
Biotechnology, Pharmaceutical, Health, Phosphodiesterase inhibitors, Branches of biology, Molecular biology, Phosphodiesterase, PD-1 and PD-L1 inhibitors, PD-L1, Biology

View the full release here: https://www.businesswire.com/news/home/20200117005292/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200117005292/en/
    Technavio has announced its latest market research report titled global PD-1 and PD-L1 inhibitors market 2019-2023.
  • The proven efficiency of PD-1 and PD-L1 inhibitors and strong pipeline are among factors anticipated to boost the growth of the market.
  • Request a free sample report
    Related Reports on Health Care include:
    MEK Inhibitors Market Global MEK Inhibitors Market by product (MEKINIST, COTELLIC, and MEKTOVI) and geography (Asia, Europe, North America, and ROW).
  • Phosphodiesterase (PDE) inhibitors Market Global Phosphodiesterase (PDE) inhibitors Market by application (oral, topical, and other RoA), and geography (Asia, Europe, North America, and ROW).

Global Phosphodiesterase (PDE) Inhibitors Market Research Report 2019-2023: Key Players are Bayer, Eli Lilly & Co, GlaxoSmithKline, Pfizer, and Vivus - ResearchAndMarkets.com

Retrieved on: 
Monday, July 29, 2019
Biotechnology, Pharmaceutical, Health, Phosphodiesterase inhibitors, Chemical compounds, Phosphodiesterase, Organic compounds, Lactams, PDE5 inhibitors, Piperazines, Phosphodiesterase-4 inhibitor

The "Global Phosphodiesterase (PDE) inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Phosphodiesterase (PDE) inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • However, potent drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and launch of generics may hamper the growth of the phosphodiesterase inhibitors industry over the forecast period.
  • The phosphodiesterase inhibitors market analysis considers sales from oral, topical, and other RoA.
  • With the presence of several major players, the global phosphodiesterase inhibitors market is fragmented.

Global Phosphodiesterase (PDE) Inhibitors Market 2019-2023| Rising Burden of Chronic Diseases to Boost Growth| Technavio

Retrieved on: 
Wednesday, July 17, 2019
Health, Pharmaceutical, Phosphodiesterase inhibitors, Molecular biology, Phosphodiesterase, PDE, Phosphodiesterase-4 inhibitor

View the full release here: https://www.businesswire.com/news/home/20190717005464/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190717005464/en/
    Technavio has announced its latest market research report titled global phosphodiesterase (PDE) inhibitors market 2019-2023.
  • This global phosphodiesterase (PDE) inhibitors market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
  • Global Phosphodiesterase (PDE) Inhibitors Market: Rising Burden of Chronic Diseases
    Chronic diseases are among the leading causes of death and contribute to a significant portion of annual healthcare expenditure.
  • Global Phosphodiesterase (PDE) Inhibitors Market: Segmentation Analysis
    This market research report segments the global phosphodiesterase (PDE) inhibitors market by application (oral, topical, other RoA) and geographical regions (North America, Europe, Asia, and ROW).